KOD — Kodiak Sciences Share Price
0.000.00%
Last trade - 00:00Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 20.88 | ||
| Price to Tang. Book | 20.88 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -91.68% | ||
| Return on Equity | -208.8% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | 47.9 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Kodiak Sciences Inc. is a precommercial retina-focused biotechnology company. The Company is developing a portfolio of three late-stage clinical programs. Zenkuda (tarcocimab tedromer) has a BLA-ready profile in diabetic retinopathy, retinal vein occlusion and wet AMD, and, together with KSI-501, is being explored in the BLA-facing Phase 3 DAYBREAK wet AMD study. KSI-101 is a bispecific protein being explored in two BLA-facing Phase 3 studies in Macular Edema Secondary to Inflammation (MESI). Its Antibody Biopolymer Conjugate (ABC) Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies. Its second investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high prevalence retinal vascular diseases to address the leading unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy.
Directors
- Victor Perlroth CHM (48)
- John Borgeson CFO (59)
- Jason Ehrlich OTH (45)
- Robert Profusek LED (71)
- Felix Baker IND (52)
- Charles Bancroft IND (61)
- Bassil Dahiyat IND (50)
- Richard Levy IND (63)
- Taiyin Yang IND (67)
- Last Annual
- December 31st, 2025
- Last Interim
- March 31st, 2026
- Incorporated
- June 22nd, 2009
- Public Since
- October 4th, 2018
- No. of Shareholders
- 21
- No. of Employees
- 130
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 62,578,441
- Address
- 1250 Page Mill Rd, PALO ALTO, 94304
- Web
- https://kodiak.com/
- Phone
- +1 3026365400
- Contact
- John Borgeson
- Auditors
- PricewaterhouseCoopers LLP
Upcoming Events for KOD
Kodiak Sciences Inc Annual Shareholders Meeting
Q2 2026 Kodiak Sciences Inc Earnings Release
Q3 2026 Kodiak Sciences Inc Earnings Release
Similar to KOD
Abivax SA
NASDAQ Global Market
Acrivon Therapeutics
NASDAQ Global Market
Actuate Therapeutics
NASDAQ Global Market
Adagene
NASDAQ Global Market
Adlai Nortye
NASDAQ Global Market
FAQ
What is the Kodiak Sciences share price?
As of Today at 03:38 UTC, shares in Kodiak Sciences are trading at $37.41. This share price information is delayed by 15 minutes.
How has the Kodiak Sciences share price performed this year?
Shares in Kodiak Sciences last closed at $37.41 and the price had moved by +958.27% over the past 365 days. In terms of relative price strength the Kodiak Sciences share price has outperformed the S&P500 Index by +730.34% over the past year.
What are the analyst and broker recommendations for Kodiak Sciences?
The overall consensus recommendation for Kodiak Sciences is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Kodiak Sciences dividend yield?
Kodiak Sciences does not currently pay a dividend.
Does Kodiak Sciences pay a dividend?
Kodiak Sciences does not currently pay a dividend.
When does Kodiak Sciences next pay dividends?
Kodiak Sciences does not currently pay a dividend.
How do I buy Kodiak Sciences shares?
To buy shares in Kodiak Sciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Kodiak Sciences?
As of the previous close price of $37.41, shares in Kodiak Sciences had a market capitalisation of $2.34bn.
Where are Kodiak Sciences shares listed?
Here are the trading details for Kodiak Sciences:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: KOD
What kind of share is Kodiak Sciences?
Based on an overall assessment of its quality, value and momentum Kodiak Sciences is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Kodiak Sciences share price forecast for 2026?
The analyst consensus target price for shares in Kodiak Sciences is $64.00. That is 71.08% above the last closing price of $37.41.
Analysts covering Kodiak Sciences currently have a consensus Earnings Per Share (EPS) forecast of -$3.76 for the next financial year.
Find out moreWhat is the trend in the Kodiak Sciences share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Kodiak Sciences. Over the past six months, its share price has outperformed the S&P500 Index by +62.2%.
As of the last closing price of $37.41, shares in Kodiak Sciences were trading +55.84% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Kodiak Sciences PE Ratio?
The Kodiak Sciences PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $37.41.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Kodiak Sciences?
Kodiak Sciences' management team is headed by:
- Victor Perlroth - CHM
- John Borgeson - CFO
- Jason Ehrlich - OTH
- Robert Profusek - LED
- Felix Baker - IND
- Charles Bancroft - IND
- Bassil Dahiyat - IND
- Richard Levy - IND
- Taiyin Yang - IND